

STANDARD OPERATING PROCEDURE

Title: Preparation of Standard Peptide Samples for the Generation of Reverse Response Curves-Experiment 1

SOP#: WU-SOP-EXP1-02

Version #: 1

Author: Petra Erdmann-Gilmore

Reviewer: Sherri Davies PhD

WU-PCC Director: R. Reid Townsend, MD, PhD

Date: 6/30/2016

Purpose

The purpose of this document is to describe the preparation of standard solutions of high purity, synthetic natural abundance (L, light) and stable isotope-labeled (H, heavy) peptides to determine the linear range, and the limits of the blank (LOB), limit of detection (LOD), and the lower limit of quantification (LLOQ) from a reverse response curve in a tumor digest matrix (<https://assays.cancer.gov/guidance-document/>). The preparation of sufficient quantities of H/L peptide standard admixtures to generate replicate measurements (n=3) at six concentrations (over four orders of magnitude) from a single freeze-thaw cycle of secondary stock solutions is described.

Scope

The detailed bench procedures for preparing admixtures of standard heavy and light peptides from high purity, quantified peptide solutions that are supplied by the vendor is described. The preparation of primary, secondary and tertiary stock solutions using diluents containing 'carrier' peptides is described. The preparation of standard samples containing matrix from a pooled tryptic digest of breast cancer patient derived xenografts (PDX) (WU-SOP-TD1-01) is provided.

The preparation of standard samples for LC-MS to generate the reverse response curves that is described in Experiment 1 in the CPTAC document, "Assay Development Guidelines" is described.

Responsibilities

It is the responsibility of person(s) performing this procedure to be familiar with laboratory safety procedures. The interpretation of results must be done by a person trained in the procedure and familiar with such interpretation.

Equipment

- Microcentrifuge, Eppendorf 5415D
- Sorval centrifuge RC6Plus; rotor: HB-6
- Rainin™ Pipet-lite XLS, P20, P200, P1000

Materials

- Axygen® MAXYmum™ recovery tips: P200 and P20: T-200-C-L-STK
P1000: T-1000-C-L-R
- Volumetric glassware (2, 5, 20, 50, 100 mL flasks): Kimble KIMAX ;rinse 3x with DI water, 3 x with 70% AcN, 1%FA, 5 x with DI water
- Autosampler vials (Sun-Sri, 200 046)
- Microcentrifuge tubes: Fisher, 02-681-333
- Microcentrifuge tube caps: 02-681-368

Reagents

- Water, LC-MS grade (Fluka, 39253-1L-R)
- Acetonitrile, LC-MS grade (Fluka, 34967-1L)
- Formic Acid, 98%, 50 mL (Fluka, 56302-50ML-F)
- Tryptic digests of proteins for TEN-MIX solutions (Michrom Bioresources Inc.)
- Yeast Alcohol Dehydrogenase (PTD/00001/36)
- Yeast Enolase (PTD/00001/46)
- Equine Cytochrome C (PTD/00001/12)
- Equine Apo-Myoglobin (PD/00001/04)
- Six Bovine Tryptic Digest Equal Molar Mix (PTD/00001/63)
- Tryptic digests of proteins for NINE-MIX solutions (Protea Biosciences, Inc.)
- Yeast Enolase (PS-217-1)
- Equine Cytochrome C (PS-200)
- Equine Myoglobin (PS-209)
- Six Bovine Tryptic Digest Equal Molar Mix (PS-215-1)
- Synthetic high purity peptides, New England Peptide.

Solutions

- **Breast Cancer Tumor Matrix (WU-SOP-TD1-01)**
The matrix for the preparation of standard samples is A tryptic digest of a pool of patient-derived breast cancer xenografts as detailed in WU-SOP-TD-01, "Preparation of purified peptides from solubilized tumor tissue—100 µg scale". . The aliquoted tryptic peptide digests were thawed on ice before spiking into the standard samples immediately prior to placing the samples in the autosampler tray

for LC-MS. The total quantity that was added to each standard vial (~1 µg) is based on the starting protein concentration of the pooled lysate and assumes complete conversion and recovery of peptides from proteins.

Procedure

1. Preparation Of Diluent Solutions

a. ACETONITRILE/FORMIC ACID (1%/1%) (AcN/FA-1)

1. Add 50 mL of LC-MS grade water to a 100 mL volumetric flask that has been labeled, initialed and dated.
2. Dispense 1.0 mL of FA (98%) and 1.0 mL of AcN into the flask.
3. Fill to volumetric flask mark with LC-MS grade water (Q.S.).
4. Store the diluent solution at room temperature for < one month.

b. ACETONITRILE/FORMIC ACID (30%/1%) (AcN/FA-30)

1. Add 50 mL of LC-MS grade water to a 100 mL volumetric flask that has been labeled, initialed, and dated.
2. Pipette 1 mL of formic acid (98%) into the flask.
3. Add 30 mL of AcN.
4. Q.S. with LC-MS grade water.
5. The solution is stored sealed at room temperature for < one month.

2. Preparation of “Carrier” Tryptic Peptide Solutions for Primary Transfer of Peptides from Vendor Vials and Dilution of the Primary Solutions.

NOTE: The naming of the diluent solutions gives the number of proteins as standard tryptic digests, the percent of acetonitrile and the concentration of total peptide content in fmol/µL. For example, Nine-MIX-1-100 is a mixture of the tryptic digests from nine non-human proteins (Tables I and II) in 1% AcN with a total peptide content of 100 fmol/µL. All solutions contain FA (1%).

Table I. Tryptic peptide digests of proteins and volumes to prepare primary stock solution (~ 1 pmol/µL).			
PROTEIN	Species	pmol/each vial	Volume (µL) to make primary solution (1 pmol/µL)
Cytochrom C	Equine	500	500
Apomyoglobin	Equine	500	500
Enolase	Yeast	500	500

Table II. Tryptic peptide digests of six bovine proteins and volume to prepare primary stock solution (1.2 pmol/ μ L).

Proteins	Species	pmol/one vendor vial	volume to make primary stock solution (1.2 pmol / μ L)
Beta Lactoglobulin	bovine	100	500
Lactoperoxidase	bovine	100	
Carbonic Anhydrase	bovine	100	
Glutamate Dehydrogenase	bovine	100	
Alpha Casein	bovine	100	
Serum Albumin	bovine	100	

3. Preparation Of NINE-MIX-30-200 Solution.

- Pipette 500 μ L of AcN/FA-30 diluent solution to each of three vendor vials containing 500 pmol of dried tryptic digests of cytochrome C, apomyoglobin, and enolase (Table I).
- Vortex vials for 30 s and spin in the microcentrifuge for 10 s at the maximum setting ($\sim 14,000$ rcf). Place the centrifuged vials on ice.
- transfer entire contents of each vial to a 50mL volumetric flask. Rinse vial with another 500 μ L of AcN/FA-30, vortex, spin and transfer entire volume to 50 mL volumetric flask.
- Add 500 μ L of AcN/FA-30 to each of 5 vendor vials that contain the tryptic digests of six bovine proteins (Table II), vortex for 30 s, centrifuge as above for 30 s and transfer entire contents of each vial to the 50 mL volumetric flask.
- QS the volumetric flask to 50 mL mark with AcN/FA-30.
- Aliquot into 4mL into each of 12 glass vials.
- Store aliquots of NINE-MIX-30-200 peptide solutions at -20°C .

4. Preparation Of NINE-MIX-30-50.

- Pipette 2500 μ L of NINE-MIX-30-200 solution into the 10 mL volumetric flask.
- QS the volumetric flask to the 10 mL mark with AcN-FA-30. Mix by inversion.
- Aliquot into 4 mL into each of 2 glass vials
- Store aliquots of NINE-MIX-30-50 peptide solutions at -20°C .

Table III. Diluents and Standard Tryptic Peptide “Carrier” Solutions		
Solution	Solvents	Peptide Concentration (fmol/μL)
AcN/FA-1	Acetonitrile/formic acid (1%/1%)	0
AcN/FA-30	Acetonitrile/formic acid (30%/1%)	0
NINE-MIX-30-50	Acetonitrile/formic acid (30%/1%)	50
NINE-MIX-30-200	Acetonitrile/formic acid (30%/1%)	200

5. Preparation of the Combined Primary Heavy and Light Peptide Stock Solutions

NOTE: A primary peptide stock solution is defined as the solution that is prepared from the vendor vial. A stock solution is prepared, frozen and thawed once to generate secondary solutions and then discarded. The synthetic peptides for this SOP are vendor quantified and qualified high purity peptides. The entire contents of each vendor vial is used to prepare the primary heavy and primary light solutions, PHS and PLS (**Figure 1**).

- a. Remove the vendor vials from all selected peptides for the designed multiplex assay from the -80 °C freezer and allow to warm to room temperature.
- b. Group into heavy and light sets.
- c. Label two 5 mL volumetric flasks as either “HEAVY” or “LIGHT” and add ~ 1 mL of the NINE-MIX-30-50 diluent.
- d. Add 15 µL of the NINE-MIX-30-200 diluent to each vendor vial.
- e. Vortex for 30 sec and spin for 30 sec in a microcentrifuge at max speed.
- f. Pipette the entire contents from the vendor vial into either the “HEAVY” or “LIGHT” labeled volumetric flask corresponding to the vendor vial label. Pipette up and down 3 times with the contents of the 5 mL volumetric flask.
- g. Rinse the vendor vial with 50 µL of NINE-MIX-30-50 and transfer the entire contents into the corresponding volumetric flask.
- h. Once all selected peptides have been transferred, Q.S. the volumetric flask with NINE-MIX-30-50 for a final concentration of ~ 20 pmol/µL for each peptide. For smaller quantity vendor vials, 5mL volumetric flasks are 2 pmol/µL. If 2mL volumetric flasks are used instead of 5mL volumetric flasks, the final concentration will be 5pmol/µL.
- i. Dispense as aliquots of the primary H or L combined peptide stock solutions (220 µL) into 500 µL screw cap vials and freeze at -80°C.
- j. The panel consists of 18 primary stock solutions. **Primary Heavy (HPS) and Primary Light (LPS)** stock solutions are combined into a single volumetric flask to prepare the **Heavy Secondary (HSS) and the Light Secondary (LSS)** stock solutions (**Figure 1**).




Figure 1. Preparation of standard admixtures of H and L peptides for the generation of reverse response curves (Experiment 1). The entire contents of grouped H or L synthetic peptides (Table V) are transferred to a 5 mL volumetric flask to prepare primary stocks, heavy primary stocks (HPS) or light primary stocks (LPS). Secondary stocks are prepared by combining and diluting all primary stocks, HSS and LSS (Table IV). The working solutions for preparing the samples for standard curve generation, the blank that contains a constant amount of L peptide (25 fmol), and the equimolar solution for building the method (WU-SOP-MS4-01) are prepared. The samples are prepared by the addition of matrix solution and then then the standards as described (Table IV).

6. Preparation of Secondary Peptide Stock Solutions by Combining HPS and LPS Solutions (Figure 1).

- Remove an aliquot of each H and L primary stock from the freezer and thaw on ice.
- Label four 2 mL volumetric flasks as HSS-400, LSS-400, HSS-20 and LSS-20.
- Transfer ~1 mL of the NINE-MIX-30-50 diluent to each flask
- Pipette into each flask the volumes from the H and L primary stocks as indicated in Table IV and Q.S. to 2 mL with NINE-MIX-30-50.
- Dispense as aliquots (55 μ L) into 500 μ L screw cap tubes and freeze at -80°C.

Table IV. Primary and Secondary Peptide Stock Solutions			
Solution	Component	Diluent	Concentration (fmol/ μ L)
Peptide Stock Solutions			
HPS LPS	Heavy (H) or Light (L) Primary Stock	NINE-MIX-30- 50	20000, 5000, 2000
HSS-400 LSS-400	Heavy (H) or Light (L) Secondary Stock	NINE-MIX-30- 50	400
HSS-20 LSS-20	Heavy (H) or Light (L) Secondary Stock	NINE-MIX-30- 50	20

7. Preparation Of Stock H/L Admixtures For Standard Reverse Curve Generation (Figure 1).

- Remove an aliquot of each of the four H and L secondary stock solutions and the two H and L primary stock solutions from the freezer and thaw on ice.
- Transfer ~1 mL of the AcN/FA-1 diluent into flasks labeled as shown in Table V.
- Pipette the indicated volumes (**Table V**) from either a H or L secondary stock solution to prepare the six varying concentrations of heavy peptides and a constant quantity of light peptides.
- Q.S. to 2 mL with TEN-MIX-30-50.
- Dispense as aliquots (55 μ L) into 500 μ L Microcentrifuge tubes and freeze at -80°C.

Table V. Diluents for Preparation of Stock Solutions (H/L) for Standard Reverse Curve Generation						
STD Stock Solution	Reagents Needed	diluent	fmol H/L	HSS (μ L)	HPS (μ L)	LSS400 (μ L)
STD01	HSS-20 & LSS-400	AcN/FA-30	0.025/25	2.5	-	125
STD02	HSS-20 & LSS-400	AcN/FA-30	0.25/25	25	-	125
STD03	HSS-20 & LSS-400	AcN/FA-30	1.0/25	100	-	125
STD04	HSS-400 & LSS-400	AcN/FA-30	5.0/25	25	-	125
STD05	HSS-400 & LSS-400	AcN/FA-30	25/25	125	-	125
STD06	HPS & LSS-400	AcN/FA-30	250/25	-	25	125

8. Preparation of Tumor Digest Matrix.

Remove an aliquot of the purified tumor digest peptides prepared according to WU-SOP-TD1-01 and dilute with AcN/FA-1, if necessary to an appropriate concentration to spike into the final standard sample (see below for example used for Experiment 1).

9. Preparation of Standards and Matrix Blanks for Six-Point Reverse Curve Data Generation.

- Remove an aliquot for each of the six H/L admixtures (**Table V**) and a vial of the tumor matrix from the freezer and thaw on ice.
- Dilute tumor matrix peptide solution 1:10 in AcN/FA-30.
- Add 8.3 μ L of the tumor matrix peptide solution to the AS vial.
- Add 5.0 μ L of the standard peptide admixtures.
- Vortex for \sim 30 sec; dry in speedvac
- Solubilize in 12.5 μ L AcN/FA-1 and vortex for \sim 30 sec.
- Centrifuge in the Sorvall centrifuge for 20 min at 8000 rpm.

10. Generating the Assay Response Curve

Standards, blanks and the equimolar solution are analyzed by *nano*-LC-MS according to WU-SOP-LC2-01 and WU-SOP-MS4-01. **Table VI** shows the injection queue. A total of 3 replicates are acquired for each of the six standard admixture concentrations. The Injection volume of STD samples is 2.5 μ L in 1 μ g tumor digest matrix.

Table IV. Reverse-Curve Run Block ¹	
Sample Injection	Run Time (h)
Matrix Blank-1	2.75
Matrix Blank-2	2.75
Matrix Blank-3	2.75
STD 01	2.75
STD 02	2.75
STD 03	2.75
STD 04	2.75
STD 05	2.75
STD 06	2.75
Matrix Blank-4	2.75
Matrix Blank-5	2.75
Matrix Blank-6	2.75
STD 01	2.75
STD 02	2.75
STD 03	2.75
STD 04	2.75
STD 05	2.75
STD 06	2.75
Matrix Blank-9	2.75
Matrix Blank-10	2.75
Matrix Blank-11	2.75
STD 01	2.75
STD 02	2.75
STD 03	2.75
STD 04	2.75
STD 05	2.75
STD 06	2.75
Matrix Blank-13	2.75
Matrix Blank-14	2.75
Matrix Blank-15	2.75
Total Run Time (Days)	3.78

Referenced Documents

- WU-SOP-TD-01, "Preparation of purified peptides from solubilized tumor tissue—100 µg scale".
- WU-SOP-LC2-01-"nano-Liquid Chromatography for Experiment 1 and 2 using EASY-nLC1000"
- WU-SOP-MS3-01-"Optimizing Mass Spectrometer Performance for Experiments 1 and 2 on the Q-Exactive™ system"
- WU-SOP-MS4-01-"Mass Spectrometry Using Parallel Reaction Monitoring for Experiments 1 and 2 on the Q-Exactive™ system"

LIST OF ABBREVIATIONS

- AcN, acetonitrile
- FA, formic acid
- LC-MS, *nano*-LC interfaced to a high-resolution Quadrupole-Orbitrap mass spectrometer as described in WU-SOP-LC2-01 and WU-SOP-MS4-01
- H or heavy, stable isotopically labeled synthetic peptide
- L or light, natural abundance synthetic peptide
- Q.S., *quantum satis*
- PDX, patient-derived xenografts
- PRM, parallel reaction monitoring
- HPS , primary stock solution of the heavy peptide; prepared by direct dilution and transfer from the vendor
- LPS, primary stock solution of the light peptide; prepared by direct dilution and transfer from the vendor vials.
- HSS, secondary stocks of the heavy primary peptide stock solution.
- LSS, secondary stocks of the light primary peptide stock solution.

Table V. Primary Stocks for Assay

Primary Stock_001 (NR)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
ABL1	NR	ATSLVDAVNSDAAK	55 nmol
ABL1	NR	LYVSSESR	70 nmol
ABL2	NR	cNKPTVYGVSPHDK	100 nmol
ABL2	NR	GAQASSGSPALPR	100 nmol
BTK	NR	ELGTGQFGVVK	100 nmol
BTK	NR	FTNSETAEHIAQGLR	100 nmol
CHUK	NR	HRPSDHSYSDSTEMVK	100 nmol
CHUK	NR	LGTGGFGNVcLYQHR	100 nmol
CSF1R	NR	NNLQFGK	100 nmol
CSF1R	NR	VVEATAFGLGK	100 nmol
CSK	NR	NVLVSEDNVAK	100 nmol
FER	NR	GNFGEVYK	100 nmol
FER	NR	PLAEQDWYHGAIPR	100 nmol
JAK1	NR	cWEFQPSNR	100 nmol
JAK1	NR	KPATEVDPTHFEK	100 nmol
JAK2	NR	EVGDYQQLHETEVLK	100 nmol
JAK2	NR	YDPLQDNTGEVAVK	100 nmol
JAK3	NR	EQGEcLSLAVLDLAR	100 nmol
JAK3	NR	LTDSQHFFcK	100 nmol
PTK2	NR	AQLSTILEEEK	100 nmol
PTK2	NR	FLKPDVR	100 nmol
PTK2B	NR	EVGYLEFTGPPQKPPR	100 nmol
PTK2B	NR	NLLDAVDQAK	100 nmol
PTK6	NR	EDVYLSHDHNIPYK	100 nmol
PTK6	NR	YVGLWDFK	100 nmol
SYK	NR	NVLLVTQHYAK	100 nmol
SYK	NR	WYAPEcINYYK	100 nmol
TANK	NR	SLGSPLLHER	100 nmol
TBK1	NR	IISNQELIYEGR	100 nmol
TBK1	NR	LAYNEEQIHK	100 nmol
YES1	NR	FQIINTEGDWWEAR	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
ABL1	NR	ATSLVDAVNSDAAK [^]	74 nmol
ABL1	NR	LYVSSESR [^]	78 nmol
ABL2	NR	cNKPTVYGVSPHDK [^]	100 nmol
ABL2	NR	GAQASSGSPALPR [^]	100 nmol
BTK	NR	ELGTGQFGVVK [^]	100 nmol
BTK	NR	FTNSETAEHIAQGLR [^]	100 nmol
CHUK	NR	HRPSDHSYSDSTEMVK [^]	100 nmol
CHUK	NR	LGTGGFGNVcLYQHR [^]	100 nmol
CSF1R	NR	NNLQFGK [^]	100 nmol
CSF1R	NR	VVEATAFGLGK [^]	100 nmol
CSK	NR	NVLVSEDNVAK [^]	100 nmol
FER	NR	GNFGEVYK [^]	100 nmol
FER	NR	PLAEQDWYHGAIPR [^]	100 nmol

JAK1	NR	cWEFQPSNR^	100 nmol
JAK1	NR	KPATEVDPTHFEK^	100 nmol
JAK2	NR	EVGDYQQLHETEVLLK^	100 nmol
JAK2	NR	YDPLQDNTGEVVAVK^	100 nmol
JAK3	NR	EQGEcLSLAVLDLAR^	100 nmol
JAK3	NR	LTTSQHFfcK^	100 nmol
PTK2	NR	AQLSTILEEEK^	100 nmol
PTK2	NR	FLKPDVR^	100 nmol
PTK2B	NR	EVGYLEFTGPPQKPPR^	100 nmol
PTK2B	NR	NLLDAVDQAK^	100 nmol
PTK6	NR	EDVYLSHDHNIPYK^	100 nmol
PTK6	NR	YVGLWDFK^	100 nmol
SYK	NR	NVLLVTQHYAK^	100 nmol
SYK	NR	WYAPecINYYK^	100 nmol
TANK	NR	SLGSPLLHER^	100 nmol
TBK1	NR	IISNQELIYEGR^	100 nmol
TBK1	NR	LAYNEEQIHK^	100 nmol
YES1	NR	FQIINTEGDWWEAR^	100 nmol

Primary Stock_002 (NR-D-C-A)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
CDKL2	NR	DIKPENILVSQSGVVK	100 nmol
DAPK1	NR	FGNDLHISNK	100 nmol
DAPK3	NR	ESLTEDEATQFLK	100 nmol
DAPK3	NR	LcHEDVEALAAIYEK	100 nmol
GAK	NR	AASAVAVcSFLcFcR	100 nmol
GAK	NR	AVLAVHPDK	100 nmol
MELK	NR	LHYNVTTR	100 nmol
NEK2	NR	FLSLASNPELLNLPSSVIK	100 nmol
NEK2	NR	ILNHDTSAK	100 nmol
ROCK1	NR	AESEQLAR	81 nmol
ROCK1	NR	NLTLQLEQESNK	61 nmol
STK33	NR	ELLDNQWLTGNK	100 nmol
STK35	NR	DLKPDNILITER	100 nmol
STK35	NR	VcAGLAPR	100 nmol
STYK1	NR	EPAGLHEVQDFLGR	100 nmol
STYK1	NR	NLVQLEGccTEK	100 nmol
TEC	NR	HAFGSIPEIIIEYHK	100 nmol
TEC	NR	HNAAGLVTR	100 nmol
TEC	NR	NDDGVIPcQNK	100 nmol
TEC	NR	SNNLDQYEWYcR	100 nmol
TGFBR1	NR	TIVLQESIGK	100 nmol
TGFBR1	NR	TLSQLSQEGIK	100 nmol
TNK1	NR	HLPEPEGGLK	100 nmol
TNK1	NR	ILGGFAPEHK	100 nmol
TYK2	NR	LTADSSHYLcHEVAPPR	100 nmol
TYK2	NR	NLVHGNVcGR	100 nmol
TYK2	NR	TLNLSQLSFHR	100 nmol
ULK1	NR	cGASVPIPVPTQVQNYQR	100 nmol
ULK1	NR	TLASPADTAGFLHSSR	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
CDKL2	NR	DIKPENILVSQSGVVK [^]	100 nmol
DAPK1	NR	FGNDLHISNK [^]	100 nmol
DAPK3	NR	ESLTEDEATQFLK [^]	100 nmol
DAPK3	NR	LcHEDVEALAAIYEK [^]	100 nmol
GAK	NR	AASAVAVcSFLcFcR [^]	100 nmol
GAK	NR	AVLAVHPDK [^]	100 nmol
MELK	NR	LHYNVTTR [^]	100 nmol
NEK2	NR	FLSLASNPPELLNPSSVIK [^]	100 nmol
NEK2	NR	ILNHDTSFAR [^]	100 nmol
ROCK1	NR	AESEQLAR [^]	79 nmol
ROCK1	NR	NLTQLQESNK [^]	65 nmol
STK33	NR	ELLDNQWLTGNK [^]	100 nmol
STK35	NR	DLKPDNILITER [^]	100 nmol
STK35	NR	VcAGLAPR [^]	100 nmol
STYK1	NR	EPAGLHEVQDFLGR [^]	100 nmol
STYK1	NR	NLVQLEGccTEK [^]	100 nmol
TEC	NR	HAFSGIPEIIEYHK [^]	100 nmol
TEC	NR	HNAAGLVTR [^]	100 nmol
TEC	NR	NDDGVIPcQNK [^]	100 nmol
TEC	NR	SNNLDQYEWYcR [^]	100 nmol
TGFBR1	NR	TIVLQESIGK [^]	100 nmol
TGFBR1	NR	TLSQLSQEGIK [^]	100 nmol
TNK1	NR	HLPEPEGGLK [^]	100 nmol
TNK1	NR	ILGGFAPEHK [^]	100 nmol
TYK2	NR	LTADSSHYLcHEVAPPR [^]	100 nmol
TYK2	NR	NLVHGNVcGR [^]	100 nmol
TYK2	NR	TLNLSQLSFHR [^]	100 nmol
ULK1	NR	cGASVPIPVPTQVQNYQR [^]	100 nmol
ULK1	NR	TLASPADTAGFLHSSR [^]	100 nmol

Primary Stock_003 (R)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
DDR1	R	EEEYLQVDLQR	100 nmol
DDR1	R	LESSDGDGAWcPAGSVFPK	100 nmol
DDR1	R	ESEQRPPFSQLHR	38 nmol
DDR2	R	DFALDVSANQPVLVAVK	100 nmol
FLT1	R	LGDLLQANVQQDGK	100 nmol
FLT1	R	VTSPNITVTLK	100 nmol
FLT3	R	GLDNGYSISK	100 nmol
FLT3	R	HPSQSALVTIVEK	100 nmol
FLT3	R	VLHELFGTDIR	100 nmol
FLT4	R	LNLSTLHDAHGNPLLLDcK	100 nmol
IGF1R	R	AENGPGPGVLVLR	100 nmol
IGF1R	R	TTINNEYNYR	100 nmol
INSR	R	cSVAAYVSAR	100 nmol
INSR	R	EPNGLIVLYEVSYSR	100 nmol
KIT	R	AVPVVSVSK	100 nmol
KIT	R	LVVQSSIDSSAFK	100 nmol
MET	R	TEFTTALQR	98 nmol

MST1R	R	GAPEGGQYPVLR	100 nmol
MST1R	R	QLPEQQLcR	100 nmol
NTRK1	R	NcLVGQGLVVK	100 nmol
NTRK1	R	SGGLPSLGLTLANVTSDLNR	100 nmol
NTRK3	R	LNSQNLy ^c INADGSQPLFR	100 nmol
NTRK3	R	VFLAE ^c YNLSPTK	100 nmol
PDGFRA	R	LVYTLTVPEATVK	100 nmol
PDGFRA	R	NVLLAQGK	100 nmol
PDGFRB	R	DSNYISK	100 nmol
PDGFRB	R	GGPIYIITEY ^c R	100 nmol
RET	R	VFDADVVPASGELVR	100 nmol
TEK	R	FQDVIGEGNFGQVLK	100 nmol
TEK	R	TYVNTTLYEK	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
DDR1	R	EEEYLQVDLQR [^]	100 nmol
DDR1	R	LESSDGDGAw ^c PAGSVFPK [^]	100 nmol
DDR1	R	ESEQRPPFSQLHR [^]	33 nmol
DDR2	R	DFALDVSANQPVLVAVK [^]	100 nmol
FLT1	R	LGDLLQANVQQDGK [^]	100 nmol
FLT1	R	VTSPNITVTLK [^]	100 nmol
FLT3	R	GLDNGYSISK [^]	100 nmol
FLT3	R	HPSQSALVTIVEK [^]	100 nmol
FLT3	R	VLHELFGTDIR [^]	100 nmol
FLT4	R	LNLSTLHDAHGNPLLLDcK [^]	100 nmol
IGF1R	R	AENGPGPGVLVLR [^]	100 nmol
IGF1R	R	TTINNEYNYR [^]	100 nmol
INSR	R	cSVAAYVSAR [^]	100 nmol
INSR	R	EPNGLIVLYEVSyr [^]	100 nmol
KIT	R	AVPVVSVSK [^]	100 nmol
KIT	R	LVVQSSIDSSAFK [^]	100 nmol
MET	R	TEFTTALQR [^]	84 nmol62
MST1R	R	GAPEGGQYPVLR [^]	100 nmol
MST1R	R	QLPEQQLcR [^]	100 nmol
NTRK1	R	NcLVGQGLVVK [^]	100 nmol
NTRK1	R	SGGLPSLGLTLANVTSDLNR [^]	100 nmol
NTRK3	R	LNSQNLy ^c INADGSQPLFR [^]	100 nmol
NTRK3	R	VFLAE ^c YNLSPTK [^]	100 nmol
PDGFRA	R	LVYTLTVPEATVK [^]	100 nmol
PDGFRA	R	NVLLAQGK [^]	100 nmol
PDGFRB	R	DSNYISK [^]	100 nmol
PDGFRB	R	GGPIYIITEY ^c R [^]	100 nmol
RET	R	VFDADVVPASGELVR [^]	100 nmol
TEK	R	FQDVIGEGNFGQVLK [^]	100 nmol
TEK	R	TYVNTTLYEK [^]	100 nmol

Primary Stock_004 (R)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
EGFR	R	cNLLEGEPR	60 nmol
EGFR	R	NYVVTDHGScVR	62 nmol
EPHA2	R	IDTIAPDEITVSSDFEAR	100 nmol
EPHA3	R	EIFTGVEYSScDTIAK	100 nmol
EPHA3	R	VVGAGEFGEVcSGR	100 nmol
EPHA4	R	GLNPLTSYVFHVR	100 nmol
EPHA4	R	TYQVcNVMEPSQNNWLR	100 nmol
EPHA7	R	FEQIVGILDK	100 nmol
EPHA8	R	AQLTSTQGPR	100 nmol
EPHA8	R	YLSDLGYVHR	100 nmol
EPHB1	R	ADFDPPPEVAcTSVPSGPR	100 nmol
EPHB1	R	SAFWSEAPYLK	100 nmol
EPHB2	R	FLEDDTSDPTYTSALGGK	38 nmol
EPHB3	R	TVAGYGQYSRPAEFETTSE	100 nmol
EPHB4	R	DLVEPWVVVR	66 nmol
EPHB4	R	FPQVVSALDK	55 nmol
EPHB6	R	AcSSLGVSGGTcR	100 nmol
ERBB2	R	LLDIDETEHADGGK	100 nmol
ERBB2	R	NNQLALTLIDTNR	100 nmol
ERBB3	R	LTFQLEPNPHTK	100 nmol
ERBB3	R	VLGSGVFGTVHK	100 nmol
FGFR1	R	DIHHIDYYK	100 nmol
FGFR1	R	HPAQLANGGLK	100 nmol
FGFR2	R	DINNIDYYK	100 nmol
FGFR2	R	YGPDGLPYLK	100 nmol
FGFR3	R	LLAVPAANTVR	100 nmol
FGFR3	R	LSSGEGPTLANVSELELPADPKWE LSR	100 nmol
FGFR4	R	VLLAVSEEYDLDR	100 nmol
FGFR4	R	YNYLLDVLER	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
EGFR	R	cNLLEGEPR [^]	62 nmol
EGFR	R	NYVVTDHGScVR [^]	41 nmol
EPHA2	R	IDTIAPDEITVSSDFEAR [^]	100 nmol
EPHA3	R	EIFTGVEYSScDTIAK [^]	100 nmol
EPHA3	R	VVGAGEFGEVcSGR [^]	100 nmol
EPHA4	R	GLNPLTSYVFHVR [^]	100 nmol
EPHA4	R	TYQVcNVMEPSQNNWLR [^]	100 nmol
EPHA7	R	FEQIVGILDK [^]	100 nmol
EPHA8	R	AQLTSTQGPR [^]	100 nmol
EPHA8	R	YLSDLGYVHR [^]	100 nmol
EPHB1	R	ADFDPPPEVAcTSVPSGPR [^]	100 nmol
EPHB1	R	SAFWSEAPYLK [^]	100 nmol
EPHB2	R	FLEDDTSDPTYTSALGGK [^]	43 nmol
EPHB3	R	TVAGYGQYSRPAEFETTSE [^]	100 nmol
EPHB4	R	DLVEPWVVVR [^]	56 nmol
EPHB4	R	FPQVVSALDK [^]	68 nmol

EPHB6	R	AcSSLGVSGGTcR [^]	100 nmol
ERBB2	R	LLDIDETEHADGGK [^]	100 nmol
ERBB2	R	NNQLALTLIDTNR [^]	100 nmol
ERBB3	R	LTFQLEPNPHTK [^]	100 nmol
ERBB3	R	VLGSGVFGTVHK [^]	100 nmol
FGFR1	R	DIHHIDYYK [^]	100 nmol
FGFR1	R	HPAQLANGGLK [^]	100 nmol
FGFR2	R	DINNIDYYK [^]	100 nmol
FGFR2	R	YGPDGLPYLK [^]	100 nmol
FGFR3	R	LLAVPAANTVR [^]	100 nmol
FGFR3	R	LSSGEGPTLANVSELELPADPKWE LSR [^]	100 nmol
FGFR4	R	VLLAVSEEYLDLR [^]	100 nmol
FGFR4	R	YNYLLDVLER [^]	100 nmol

Primary Stock_005 (M-MSC-SRC)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
AAK1	MSC	AAEDSNLISGFDVPEGS DK	100 nmol
AAK1	MSC	GHYVLCDFGSATNK	100 nmol
ADCK3	MSC	AVLGSSPFLSEANAER	100 nmol
ADCK3	MSC	VALLDFGATR	100 nmol
ADK	MSC	SLIANLAAANcYK	100 nmol
ADK	MSC	YSLKPNDQILAEDK	58 nmol
BLK	SRC	LYAVVTK	100 nmol
BLK	SRC	VESLEMER	100 nmol
CSNK1A1	M	ILQGGVGIPHIR	100 nmol
CSNK1A1	M	YASINAHLGIEQSR	100 nmol
CSNK1D	M	GAPVNISSDLTGR	100 nmol
CSNK1D	M	VASSGLQSVVHR	100 nmol
CSNK1E	M	GAPANVSSDLTGR	100 nmol
CSNK1E	M	IQPAGNTSPR	100 nmol
DCK	M	DAEKPVLFFER	100 nmol
DCK	M	NEEQGIPLEYLEK	100 nmol
ERN1	M	DVLGHGAEGTIVYR	100 nmol
ERN1	M	LTPTLYVGK	100 nmol
FGR	SRC	QLLSPGNPQGAFLIR	100 nmol
LYN	SRC	VLEEHEGEWWK	66 nmol
PRKG1	MSC	AQGISAEPQTYR	100 nmol
PRKG1	MSC	SVPTFQSLPEILSK	100 nmol
SRC	SRC	GAYcLSVSDFDNAK	100 nmol
SRC	SRC	LDSGGFYITSR	100 nmol
SRMS	SRC	SSPEERPSFATLR	100 nmol
TRPM6	MSC	EIGQcAIQISDYLK	100 nmol
TRPM6	MSC	NLSGSSEIGQGAWVK	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
AAK1	MSC	AAEDSNLISGFDVPEGS DK [^]	100 nmol
AAK1	MSC	GHYVLCDFGSATNK [^]	100 nmol
ADCK3	MSC	AVLGSSPFLSEANAER [^]	100 nmol
ADCK3	MSC	VALLDFGATR [^]	100 nmol

ADK	MSC	SLIANLAAANcYK^	100 nmol
ADK	MSC	YSLKPNDQILAEDK^	43 nmol
BLK	SRC	LYAVVTK^	100 nmol
BLK	SRC	VESLEMER^	100 nmol
CSNK1A1	M	ILQGGVGIPHIR^	100 nmol
CSNK1A1	M	YASINAHLGIEQSR^	100 nmol
CSNK1D	M	GAPVNISSDLTGR^	100 nmol
CSNK1D	M	VASSGLQSVVHR^	100 nmol
CSNK1E	M	GAPANVSSDLTGR^	100 nmol
CSNK1E	M	IQPAGNTSPR^	100 nmol
DCK	M	DAEKPVLFFER^	100 nmol
DCK	M	NEEQGIPLEYLEK^	100 nmol
ERN1	M	DVLGHGAEGTIVYR^	100 nmol
ERN1	M	LTPTLYVGK^	100 nmol
FGR	SRC	QLLSPGNPQGAFLIR^	100 nmol
LYN	SRC	VLEEHGEWWK^	65 nmol
PRKG1	MSC	AQGISAEPQTYR^	100 nmol
PRKG1	MSC	SVPTFQSLPEEILSK^	100 nmol
SRC	SRC	GAYcLSVSDFDNAK^	100 nmol
SRC	SRC	LDSGGFYITSR^	100 nmol
SRMS	SRC	SSPEERPSFATLR^	100 nmol
TRPM6	MSC	EIGQcAIQISDYLK^	100 nmol
TRPM6	MSC	NLSGSSEIGQGAWVK^	100 nmol

Primary Stock_006 (T-N)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
ACVR1	T	NITAQLPTK	100 nmol
CLK1	T	SEIQVLEHLNTTDPNSTFR	100 nmol
CLK1	T	SVNFLHSNK	100 nmol
CLK2	T	LTLGEALQHPFFAR	100 nmol
CLK2	T	YEIVSTLGEETFGR	100 nmol
CLK4	T	ITLDEALQHPFFDLLK	100 nmol
CLK4	T	SEIQVLEHLNSTDPNSVFR	100 nmol
DCLK3	T	QVSPSSEGHFR	100 nmol
DCLK3	T	VIGDGNFAVVK	100 nmol
EIF2AK1	T	IGDFGLAcTDILQK	100 nmol
EIF2AK1	T	NIFLHGPDQQVK	100 nmol
EIF2AK4	T	GLSNESVNLLK	100 nmol
EIF2AK4	T	IGDFGLATDHLAFSADSK	100 nmol
IKBKB	N	LTHPNVVAAR	100 nmol
IKBKB	N	QGGTLDLEEQR	100 nmol
IKBKE	N	GVLGAGYQALR	77 nmol
IKBKE	N	PAGAIAGAQR	38 nmol
IRAK1	N	GPNQPVESDES LGGLSAALR	100 nmol
IRAK1	N	TASVLWPWINR	100 nmol
IRAK3	N	SSISFQNIIEGTR	100 nmol
IRAK3	N	VEIQNLTYAVK	100 nmol
IRAK4	N	LSDFIDPQEGWK	100 nmol
IRAK4	N	SANILLDEAFTAK	100 nmol
ITK	N	LATGcAQYDPTK	100 nmol
ITK	N	TAGTYTVSVFTK	100 nmol

NLK	N	EIIHQFILEQQK	100 nmol
NLK	N	IIVSPQPLSSDHVK	100 nmol
SRPK1	T	IIQQVLQGLDYLHTK	100 nmol
SRPK1	T	STAGNFLVNPLEPK	100 nmol
SRPK2	T	AADLLVNPLDPR	100 nmol
SRPK2	T	TRAADLLVNPLDPR	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
ACVR1	T	NITAQLPTK [^]	100 nmol
CLK1	T	SEIQVLEHLNTTDPNSTFR [^]	100 nmol
CLK1	T	SVNFLHSNK [^]	100 nmol
CLK2	T	LTLGEALQHPFFAR [^]	100 nmol
CLK2	T	YEIVSTLGEFTGR [^]	100 nmol
CLK4	T	ITLDEALQHPFFDLLK [^]	100 nmol
CLK4	T	SEIQVLEHLNSTDPNSVFR [^]	100 nmol
DCLK3	T	QVSPSSEGHFR [^]	100 nmol
DCLK3	T	VIGDGNFAVVK [^]	100 nmol
EIF2AK1	T	IGDFGLAcTDILQK [^]	100 nmol
EIF2AK1	T	NIFLHGPDQQVK [^]	100 nmol
EIF2AK4	T	GLSNESVNLLK [^]	100 nmol
EIF2AK4	T	IGDFGLATDHLAFSADSK [^]	100 nmol
IKBKB	N	LTHPNVVAAR [^]	100 nmol
IKBKB	N	QGGTLDLEEQR [^]	100 nmol
IKBKE	N	GVLGAGYQALR [^]	54 nmol
IKBKE	N	PAGAIAGAQR [^]	70 nmol
IRAK1	N	GPNQPVESDESGLGLSALR [^]	100 nmol
IRAK1	N	TASVLWPWINR [^]	100 nmol
IRAK3	N	SSISFQNIIEGTR [^]	100 nmol
IRAK3	N	VEIQNLTYAVK [^]	100 nmol
IRAK4	N	LSDFIDPQEGWK [^]	100 nmol
IRAK4	N	SANILLDEAFTAK [^]	100 nmol
ITK	N	LATGcAQYDPTK [^]	100 nmol
ITK	N	TAGTYTVSVFTK [^]	100 nmol
NLK	N	EIIHQFILEQQK [^]	100 nmol
NLK	N	IIVSPQPLSSDHVK [^]	100 nmol
SRPK1	T	IIQQVLQGLDYLHTK [^]	100 nmol
SRPK1	T	STAGNFLVNPLEPK [^]	100 nmol
SRPK2	T	AADLLVNPLDPR [^]	100 nmol
SRPK2	T	TRAADLLVNPLDPR [^]	100 nmol

Primary Stock_007 (P)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
PHKG2	P	ELcGTPGYLAPEILK	100 nmol
PHKG2	P	LTAEQALQHPFFER	100 nmol
PI4KB	P	GTPLELVNGDGVDSER	100 nmol
PI4KB	P	SDATASISLSSNLK	100 nmol
PIK3CA	P	DDGQLFHIDFGHFLDHK	100 nmol
PIK3CA	P	TGIYHGGEPLcDNVNTQR	100 nmol
PIK3CA	P	YEQYLDNLLVR	100 nmol
PIK3CB	P	IGQFLFWHLR	100 nmol
PIK3CB	P	VFGEDSVGVIFK	100 nmol

PIK3CD	P	KPSSVSLWSLEQPFR	100 nmol
PIK3CD	P	TVSSSEVSVcSEP VWK	100 nmol
PIK3CG	P	DHESVFTVSLWDcDR	100 nmol
PIK3CG	P	IQQSTVGNTGAFK	100 nmol
PIK3CG	P	LGP HHFLLLYQK	100 nmol
PIK3R2	P	GcYAcSVVVDGDTK	100 nmol
PIK3R2	P	TATGFGFAEPYNLYGSLK	100 nmol
PIP4K2C	P	FGIDDQDYLVS LTR	100 nmol
PRKAA1	P	FEcSEEEVLS cLYNR	100 nmol
PRKAA1	P	IGHYILGDTLGVGTFGK	100 nmol
PRKAA1	P	VPFLVAETPR	100 nmol
PRKACB	P	ILQAVNFPFLVR	100 nmol
PRKX	P	LFWTW HDER	100 nmol
PRKX	P	SVDWEAVPQR	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
PHKG2	P	ELcGTPGYLAPEILK [^]	100 nmol
PHKG2	P	LTAEQALQHPFFER [^]	100 nmol
PI4KB	P	GTPLELVNGDGV DSEIR [^]	100 nmol
PI4KB	P	SDATASISLSSNLK [^]	100 nmol
PIK3CA	P	DDGQLFHIDFGHFLD HK [^]	100 nmol
PIK3CA	P	TGIYHGGEPLcDNVNTQR [^]	100 nmol
PIK3CA	P	YEQYLDNLLVR [^]	100 nmol
PIK3CB	P	IGQFLFWHLR [^]	100 nmol
PIK3CB	P	VFGEDSVGVIFK [^]	100 nmol
PIK3CD	P	KPSSVSLWSLEQPFR [^]	100 nmol
PIK3CD	P	TVSSSEVSVcSEP VWK [^]	100 nmol
PIK3CG	P	DHESVFTVSLWDcDR [^]	100 nmol
PIK3CG	P	IQQSTVGNTGAFK [^]	100 nmol
PIK3CG	P	LGP HHFLLLYQK [^]	100 nmol
PIK3R2	P	GcYAcSVVVDGDTK [^]	100 nmol
PIK3R2	P	TATGFGFAEPYNLYGSLK [^]	100 nmol
PIP4K2C	P	FGIDDQDYLVS LTR [^]	100 nmol
PRKAA1	P	FEcSEEEVLS cLYNR [^]	100 nmol
PRKAA1	P	IGHYILGDTLGVGTFGK [^]	100 nmol
PRKAA1	P	VPFLVAETPR [^]	100 nmol
PRKACB	P	ILQAVNFPFLVR [^]	100 nmol
PRKX	P	LFWTW HDER [^]	100 nmol
PRKX	P	SVDWEAVPQR [^]	100 nmol

Primary Stock_008 (P)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
FRK	P	ERPTFETLR	87 nmol
FRK	P	GEFSLSVLDGAVVK	54 nmol
GSK3A	P	DIKPQNLLVDPDTAVLK	100 nmol
GSK3A	P	LSPLEAcAHSFFDEL R	100 nmol
GSK3B	P	DIKPQNLLLD PDTAVLK	100 nmol
GSK3B	P	LTPLEAcAHSFFDEL R	100 nmol
MTOR	P	AVLALHQDLFSLAQQcIDK	100 nmol
MTOR	P	DASAVSLSESK	100 nmol

RPS6KA1	P	ETIGVGSYSEcK	100 nmol
RPS6KA1	P	NLVFSDGYVVK	100 nmol
RPS6KA2	P	LGAGIDGVVEIK	100 nmol
RPS6KA3	P	EASAVLFTITK	100 nmol
RPS6KA3	P	FSLSGGYWNSVSDTAK	100 nmol
RPS6KA4	P	HFSESEASQILR	100 nmol
RPS6KA4	P	ITEANLTGHEEK	100 nmol
RPS6KA6	P	GFSFVATSIAEEYK	100 nmol
RPS6KA6	P	TVDYHLcQGVVHR	100 nmol
RPS6KB1	P	IRPEcFELLR	100 nmol
RPS6KB1	P	LNLPPYLTQEAR	100 nmol
RPS6KB2	P	EGFSFQPK	100 nmol
RPS6KB2	P	HPFIVELAYAFQTGGK	100 nmol
SGK3	P	EScPSVSIPSSDEHR	100 nmol
SGK3	P	IPPPFNPNVAGPDDIR	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
FRK	P	ERPTFETLR^	62 nmol
FRK	P	GEFSLSVLDGAVVK^	76 nmol
GSK3A	P	DIKPQNLLVDPDTAVLK^	100 nmol
GSK3A	P	LSPLEAcAHSFFDELRL^	100 nmol
GSK3B	P	DIKPQNLLLDPDPTAVLK^	100 nmol
GSK3B	P	LTPLEAcAHSFFDELRL^	100 nmol
MTOR	P	AVLALHQDLFSLAQQcIDK^	100 nmol
MTOR	P	DASAVSLSESK^	100 nmol
RPS6KA1	P	ETIGVGSYSEcK^	100 nmol
RPS6KA1	P	NLVFSDGYVVK^	100 nmol
RPS6KA2	P	LGAGIDGVVEIK^	100 nmol
RPS6KA3	P	EASAVLFTITK^	100 nmol
RPS6KA3	P	FSLSGGYWNSVSDTAK^	100 nmol
RPS6KA4	P	HFSESEASQILR^	100 nmol
RPS6KA4	P	ITEANLTGHEEK^	100 nmol
RPS6KA6	P	GFSFVATSIAEEYK^	100 nmol
RPS6KA6	P	TVDYHLcQGVVHR^	100 nmol
RPS6KB1	P	IRPEcFELLR^	100 nmol
RPS6KB1	P	LNLPPYLTQEAR^	100 nmol
RPS6KB2	P	EGFSFQPK^	100 nmol
RPS6KB2	P	HPFIVELAYAFQTGGK^	100 nmol
SGK3	P	EScPSVSIPSSDEHR^	100 nmol
SGK3	P	IPPPFNPNVAGPDDIR^	100 nmol

Primary Stock_009 (P-AKT)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
AKT1	P	EEWTTAIQTIVADGLK	10 nmol
AKT1	P	FFAGIVWQHVEYK	10 nmol
AKT2	P	YDSLGLLELDQR	10 nmol
AKT2	P	YFDDEFTAQSITITPPDR	10 nmol
AKT3	P	HSFFSGVNWQDVYDK	10 nmol
AKT3	P	YFDEEFTAQTITITPPEK	10 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
AKT1	P	EEWTTAIQTVADGLK [^]	10 nmol
AKT1	P	FFAGIVWQHVEK [^]	10 nmol
AKT2	P	YDSLGLLELDQR [^]	10 nmol
AKT2	P	YFDDEFTAQSITITPPDR [^]	10 nmol
AKT3	P	HSFFSGVNWQDVYDK [^]	10 nmol
AKT3	P	YFDEEFTAQTITITPPEK [^]	10 nmol

Primary Stock_010 (P-AKT)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
AKT1	P	EVIVAKDEVAHTLTENR	100 nmol
AKT1	P	FYGAEIVSALDYLHSEK	100 nmol
AKT1	P	NDGTFIGYK	100 nmol
AKT1	P	RPHFPQFSYSASGTA	53 nmol
AKT1	P	TFCGTPEYLAPEVLEDNDYGR	22 nmol
AKT2	P	AIQMVANSLK	69 nmol
AKT2	P	EGISDGATMK	76 nmol
AKT2	P	EVIIAKDEVAHTVTESR	100 nmol
AKT2	P	FYGAEIVSALEYLHSR	100 nmol
AKT2	P	SDGSFIGYK	100 nmol
AKT2	P	THFPQFSYSASIRE	37 nmol
AKT3	P	EVIIAKDEVAHTLTESR	100 nmol
AKT3	P	FYGAEIVSALDYLHSGK	100 nmol
AKT3	P	RPHFPQFSYSASGRE	36 nmol
AKT3	P	TDGSFIGYK	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
AKT1	P	EVIVAKDEVAHTLTENR [^]	100 nmol
AKT1	P	FYGAEIVSALDYLHSEK [^]	100 nmol
AKT1	P	NDGTFIGYK [^]	100 nmol
AKT1	P	RPHFPQFSYSASGTA [^]	47 nmol
AKT1	P	TFCGTPEYLAPEVLEDNDYGR [^]	53 nmol
AKT2	P	AIQMVANSLK [^]	69 nmol
AKT2	P	EGISDGATMK [^]	67 nmol
AKT2	P	EVIIAKDEVAHTVTESR [^]	100 nmol
AKT2	P	FYGAEIVSALEYLHSR [^]	100 nmol
AKT2	P	SDGSFIGYK [^]	100 nmol
AKT2	P	THFPQFSYSASIRE [^]	55 nmol
AKT3	P	EVIIAKDEVAHTLTESR [^]	100 nmol
AKT3	P	FYGAEIVSALDYLHSGK [^]	100 nmol
AKT3	P	RPHFPQFSYSASGRE [^]	45 nmol
AKT3	P	TDGSFIGYK [^]	100 nmol

Primary Stock_011 (MAPK)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
ARAF	MAPK	GPPANGAEPSR	100 nmol
ARAF	MAPK	VSQPTAEQAQAFK	100 nmol

BRAF	MAPK	GLIPEccAVYR	100 nmol
BRAF	MAPK	LTQEHIALLDK	100 nmol
MAP2K1	MAPK	ISELGAGNGGVVFK	100 nmol
MAP2K5	MAPK	GLTYLWSLK	100 nmol
MAP2K5	MAPK	LcDFGVSTQLVNSIAK	100 nmol
MAP2K6	MAPK	HVPSGQIMAVK	36 nmol
MAP2K7	MAPK	DVKPSNILLDER	100 nmol
MAP2K7	MAPK	SPSSESSQHTPPARPR	100 nmol
MAP3K2	MAPK	AQSYPDNHQEFSDYDNPIFEK	29 nmol
MAP3K3	MAPK	ASQSAGDINTIYQPPEPR	100 nmol
MAP3K3	MAPK	SPSAPINWR	100 nmol
MAP3K7	MAPK	GAFGVVcK	100 nmol
MAP3K7	MAPK	IAATTAYSKPK	100 nmol
MAP4K2	MAPK	LQQQVPLSIPTNR	100 nmol
MAP4K2	MAPK	SLDTNEVTQEITDETR	100 nmol
MAP4K3	MAPK	ASQLYSHNLPGLFDYAR	100 nmol
MAP4K3	MAPK	ETLQGLYYLHSEK	100 nmol
TAOK3	MAPK	EVETHANNSSIELEK	100 nmol
TAOK3	MAPK	IEEELAAALQK	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
ARAF	MAPK	GPPANGAEPSSR^	100 nmol
ARAF	MAPK	VSQPTAEQAQAFK^	100 nmol
BRAF	MAPK	GLIPEccAVYR^	100 nmol
BRAF	MAPK	LTQEHIALLDK^	100 nmol
MAP2K1	MAPK	ISELGAGNGGVVFK^	100 nmol
MAP2K5	MAPK	GLTYLWSLK^	100 nmol
MAP2K5	MAPK	LcDFGVSTQLVNSIAK^	100 nmol
MAP2K6	MAPK	HVPSGQIMAVK^	48 nmol
MAP2K7	MAPK	DVKPSNILLDER^	100 nmol
MAP2K7	MAPK	SPSSESSQHTPPARPR^	100 nmol
MAP3K2	MAPK	AQSYPDNHQEFSDYDNPIFEK^	30 nmol
MAP3K3	MAPK	ASQSAGDINTIYQPPEPR^	100 nmol
MAP3K3	MAPK	SPSAPINWR^	100 nmol
MAP3K7	MAPK	GAFGVVcK^	100 nmol
MAP3K7	MAPK	IAATTAYSKPK^	100 nmol
MAP4K2	MAPK	LQQQVPLSIPTNR^	100 nmol
MAP4K2	MAPK	SLDTNEVTQEITDETR^	100 nmol
MAP4K3	MAPK	ASQLYSHNLPGLFDYAR^	100 nmol
MAP4K3	MAPK	ETLQGLYYLHSEK^	100 nmol
TAOK3	MAPK	EVETHANNSSIELEK^	100 nmol
TAOK3	MAPK	IEEELAAALQK^	100 nmol

Primary Stock_012 (MAPK)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
MAPK1	MAPK	VADPDHDHTGFLTEYVATR	54 nmol
MAPK10	MAPK	LFPDSLFPADSEHNK	100 nmol
MAPK10	MAPK	VDNQFYSEVVDSTFTVLK	100 nmol
MAPK11	MAPK	ALFPGSDYIDQLK	100 nmol
MAPK12	MAPK	LYRPFQSEFAK	100 nmol
MAPK12	MAPK	VTGTPPAEFVQR	100 nmol
MAPK13	MAPK	SYIQSLPQTPR	100 nmol
MAPK13	MAPK	VTGVPGTEFVQK	100 nmol
MAPK14	MAPK	LSRPFQSIHAK	100 nmol
MAPK14	MAPK	LVGTPGAELLK	100 nmol
MAPK15	MAPK	APEVLLSSHR	100 nmol
MAPK15	MAPK	MFSTSALQGAQGGAR	100 nmol
MAPK15	MAPK	VASVQQVPPR	100 nmol
MAPK3	MAPK	IADPEHDHTGFLTEYVATR	30 nmol
MAPK7	MAPK	DILRPTVPYGEFK	100 nmol
MAPK7	MAPK	EEDGEDGSAEPPGPVK	100 nmol
MAPK8	MAPK	LFPDVLFPADSEHNK	100 nmol
MAPK8	MAPK	NIIGLLNVFTPQK	100 nmol
MAPK9	MAPK	EHAIEEWK	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
MAPK1	MAPK	VADPDHDHTGFLTEYVATR^	36 nmol
MAPK10	MAPK	LFPDSLFPADSEHNK^	100 nmol
MAPK10	MAPK	VDNQFYSEVVDSTFTVLK^	100 nmol
MAPK11	MAPK	ALFPGSDYIDQLK^	100 nmol
MAPK12	MAPK	LYRPFQSEFAK^	100 nmol
MAPK12	MAPK	VTGTPPAEFVQR^	100 nmol
MAPK13	MAPK	SYIQSLPQTPR^	100 nmol
MAPK13	MAPK	VTGVPGTEFVQK^	100 nmol
MAPK14	MAPK	LSRPFQSIHAK^	100 nmol
MAPK14	MAPK	LVGTPGAELLK^	100 nmol
MAPK15	MAPK	APEVLLSSHR^	100 nmol
MAPK15	MAPK	MFSTSALQGAQGGAR^	100 nmol
MAPK15	MAPK	VASVQQVPPR^	100 nmol
MAPK3	MAPK	IADPEHDHTGFLTEYVATR^	31 nmol
MAPK7	MAPK	DILRPTVPYGEFK^	100 nmol
MAPK7	MAPK	EEDGEDGSAEPPGPVK^	100 nmol
MAPK8	MAPK	LFPDVLFPADSEHNK^	100 nmol
MAPK8	MAPK	NIIGLLNVFTPQK^	100 nmol
MAPK9	MAPK	EHAIEEWK^	100 nmol

Primary Stock_013 (C)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
ATM	C	LDAScAANNPSLK	100 nmol
ATM	C	LQQTAFENAYLK	100 nmol
ATM	C	QDLLFLDMLK	100 nmol
AURKA	C	DIKPENLLLGSAGELK	100 nmol
AURKA	C	VYLILEYAPLGTVYR	100 nmol
AURKB	C	HFTIDDFEIGRPLGK	100 nmol
AURKB	C	LPLAQVSAHPWVR	100 nmol
CDC42BPB	C	AILTAAIVDADR	100 nmol
CDC42BPB	C	DIKPDNVLLDVNGHIR	100 nmol
CDK11A	C	ELGTPSEK	100 nmol
CDK11A	C	IYIVMNYVEHDLK	100 nmol
CDK15	C	DLKPQNLLISHLGELK	100 nmol
CDK15	C	INGQLVALK	100 nmol
CIT	C	ESQLTALQAAR	100 nmol
CIT	C	VLDNQIK	100 nmol
DYRK1A	C	IQPYALQHSFFK	100 nmol
DYRK1A	C	IVEVLGIPPAHILDQAPK	100 nmol
DYRK1B	C	ISPLGALQHGFFR	100 nmol
LATS1	C	FYIAELTcAVESVHK	100 nmol
LATS1	C	LWSDDNEEENVNDTLNGWYK	100 nmol
PLK1	C	ALTEPEAR	177 nmol
PLK1	C	LGNLFLNEDLEVK	53 nmol
PLK4	C	HYTLcGTPNYISPEIATR	100 nmol
PLK4	C	IADFGLATQLK	100 nmol
SLK	C	AGNILFTLDGDIK	55 nmol
SLK	C	LQEQEVFFK	96 nmol
STK10	C	ALDESHNQNLK	100 nmol
STK10	C	SLHINGGGSAAEQR	100 nmol
STK11	C	DIKPGNLLLTTGGTLK	100 nmol
STK11	C	NVIQLVDVLYNEEK	100 nmol
WEE1	C	FLANEVLQENYTHLPK	37 nmol
WEE1	C	HSVLLSASR	69 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
ATM	C	LDAScAANNPSLK [^]	100 nmol
ATM	C	LQQTAFENAYLK [^]	100 nmol
ATM	C	QDLLFLDMLK [^]	100 nmol
AURKA	C	DIKPENLLLGSAGELK [^]	100 nmol
AURKA	C	VYLILEYAPLGTVYR [^]	100 nmol
AURKB	C	HFTIDDFEIGRPLGK [^]	100 nmol
AURKB	C	LPLAQVSAHPWVR [^]	100 nmol
CDC42BPB	C	AILTAAIVDADR [^]	100 nmol
CDC42BPB	C	DIKPDNVLLDVNGHIR [^]	100 nmol
CDK11A	C	ELGTPSEK [^]	100 nmol
CDK11A	C	IYIVMNYVEHDLK [^]	100 nmol
CDK15	C	DLKPQNLLISHLGELK [^]	100 nmol
CDK15	C	INGQLVALK [^]	100 nmol
CIT	C	ESQLTALQAAR [^]	100 nmol
CIT	C	VLDNQIK [^]	100 nmol

DYRK1A	C	IQPYALQHSFFK^	100 nmol
DYRK1A	C	IVEVLGIPPAHILDQAPK^	100 nmol
DYRK1B	C	ISPLGALQHGFFR^	100 nmol
LATS1	C	FYIAELTcAVESVHK^	100 nmol
LATS1	C	LWSDDNEEENVNDTLNGWYK^	100 nmol
PLK1	C	ALTEPEAR^	102 nmol
PLK1	C	LGNLFLNEDLEVK^	56 nmol
PLK4	C	HYTLcGTPNYISPEIATR^	100 nmol
PLK4	C	IADFGLATQLK^	100 nmol
SLK	C	AGNILFTLDGDIK^	55 nmol
SLK	C	LQEQEVFFK^	64 nmol
STK10	C	ALDESHNQNLK^	100 nmol
STK10	C	SLHINGGGSAAEQR^	100 nmol
STK11	C	DIKPGNLLLTGGTLK^	100 nmol
STK11	C	NVIQLVDVLYNEEK^	100 nmol
WEE1	C	FLANEVLQENYTHLPK^	38 nmol
WEE1	C	HSVLLSASR^	72 nmol

Primary Stock_014 (C-CDK)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
CDK1	CDK	LESEEEGVPSTAIR	100 nmol
CDK1	CDK	VYTDEVVTLWYR	51 nmol
CDK10	CDK	FPWLSEAGLR	100 nmol
CDK2	CDK	ELNHPNIVK	100 nmol
CDK2	CDK	TYTHEVVTLWYR	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
CDK1	CDK	LESEEEGVPSTAIR^	100 nmol
CDK1	CDK	VYTDEVVTLWYR^	100 µg
CDK10	CDK	FPWLSEAGLR^	100 nmol
CDK2	CDK	ELNHPNIVK^	100 nmol
CDK2	CDK	TYTHEVVTLWYR^	100 nmol

Primary Stock_015 (C-CDK)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
CDK10	CDK	TADFGLAR	100 nmol
CDK12	CDK	DTGELVALK	100 nmol
CDK13	CDK	VENNLIVDK	100 nmol
CDK14	CDK	LQEEEGTPFTAIR	100 nmol
CDK14	CDK	LSYVNHAEDLASK	100 nmol
CDK16	CDK	LDSDGADLLTK	100 nmol
CDK16	CDK	LPDTTSIFALK	100 nmol
CDK17	CDK	FLQYESK	100 nmol
CDK17	CDK	IHALPESVSIFSLK	100 nmol
CDK18	CDK	LPQEFLQK	100 nmol
CDK2	CDK	APEILLGCK	100 nmol
CDK2	CDK	LTGEVVALK	100 nmol
CDK4	CDK	APPPGLPAETIK	100 nmol

CDK4	CDK	YEPVAEIGVGAYGTVYK	100 nmol
CDK5	CDK	AFGIPVR	100 nmol
CDK5	CDK	SFLFQLLK	100 nmol
CDK6	CDK	HLETFEHPNVVR	100 nmol
CDK6	CDK	VPEPGVPTETIK	100 nmol
CDK7	CDK	LDFLGEGQFATVYK	100 nmol
CDK7	CDK	NTNQIVAIK	100 nmol
CDK8	CDK	HPNVISLQK	100 nmol
CDK8	CDK	NTYTNC SLIK	100 nmol
CDK9	CDK	HENVVN LIEICR	100 nmol
CDK9	CDK	LLVLDPAQR	100 nmol
CDKL5	CDK	DIKPENLLISHNDVLK	100 nmol
CDKL5	CDK	NLSEGN NANYTEYVATR	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
CDK10	CDK	TADFG LAR^	100 nmol
CDK12	CDK	DTGEL VALK^	100 nmol
CDK13	CDK	VENNLIVDK^	100 nmol
CDK14	CDK	LQEEEGTPFTAIR^	100 nmol
CDK14	CDK	LSYVNHAEDLASK^	100 nmol
CDK16	CDK	LDSDGADLLTK^	100 nmol
CDK16	CDK	LPDTTSIFALK^	100 nmol
CDK17	CDK	FLQYESK^	100 nmol
CDK17	CDK	IHALPESVSIFSLK^	100 nmol
CDK18	CDK	LPQEFLQK^	100 nmol
CDK2	CDK	APELLGCK^	100 nmol
CDK2	CDK	LTGEVVALK^	100 nmol
CDK4	CDK	APPPGLPAETIK^	100 nmol
CDK4	CDK	YEPVAEIGVGAYGTVYK^	100 nmol
CDK5	CDK	AFGIPVR^	100 nmol
CDK5	CDK	SFLFQLLK^	100 nmol
CDK6	CDK	HLETFEHPNVVR^	100 nmol
CDK6	CDK	VPEPGVPTETIK^	100 nmol
CDK7	CDK	LDFLGEGQFATVYK^	100 nmol
CDK7	CDK	NTNQIVAIK^	100 nmol
CDK8	CDK	HPNVISLQK^	100 nmol
CDK8	CDK	NTYTNC SLIK^	100 nmol
CDK9	CDK	HENVVN LIEICR^	100 nmol
CDK9	CDK	LLVLDPAQR^	100 nmol
CDKL5	CDK	DIKPENLLISHNDVLK^	100 nmol
CDKL5	CDK	NLSEGN NANYTEYVATR^	100 nmol

Primary Stock_016 (D)
Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
BMP2K	D	FPAAGLEQEEFDVFTK	100 nmol
BMPR1B	D	DLHPTLPPLK	100 nmol
BMPR1B	D	NGTccIADLGLAVK	100 nmol
ICK	D	QHQSQPPLHLTPYK	100 nmol
ICK	D	QLGDGTYGSVLLGR	100 nmol
LIMK1	D	GcFGQAIK	100 nmol
LIMK1	D	SPGAGSLGSPASQR	100 nmol
MARK2	D	ASLGQASIQNGK	67 nmol
MARK2	D	FLILNPSK	97 nmol
MARK3	D	TPVASTHSISSAATPDR	100 nmol
MARK3	D	YDEITATYLLGR	100 nmol
MYLK	D	LQDVHVAEGK	100 nmol
MYLK	D	TVTINTEQK	100 nmol
MYLK3	D	GSLGPTLTTEAPAAAQPGK	100 nmol
MYLK3	D	STGLPLAAK	100 nmol
NUAK2	D	EQKPPQASGLLLHR	100 nmol
NUAK2	D	IADFGLSNLYHQGK	100 nmol
PAK1	D	DAGTLNHGSKPLPPNPEEK	100 nmol
PAK1	D	SAEDYNSSNALNVK	100 nmol
PAK4	D	SYLDNFIK	82 nmol
PAK7	D	SLYGDDLDPYR	100 nmol
PAK7	D	THPQGHSYNSYTYPR	100 nmol
PHKG1	D	AALFENTPK	100 nmol
PHKG1	D	LTDFGFSQLEPGER	100 nmol
PKN1	D	ALQAGQLENQAAPDDTQGSPDLG AVELR	100 nmol
PKN1	D	VLLSEFRPSGELFAIK	100 nmol
PKN2	D	PAALTGTLEVR	61 nmol
RIOK2	D	ESDIYIVANEEGQQFALK	100 nmol
RIOK2	D	FSYESELFPTFK	100 nmol
ROS1	D	TSFQFYSTLPNTIYR	100 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
BMP2K	D	FPAAGLEQEEFDVFTK [^]	100 nmol
BMPR1B	D	DLHPTLPPLK [^]	100 nmol
BMPR1B	D	NGTccIADLGLAVK [^]	100 nmol
ICK	D	QHQSQPPLHLTPYK [^]	100 nmol
ICK	D	QLGDGTYGSVLLGR [^]	100 nmol
LIMK1	D	GcFGQAIK [^]	100 nmol
LIMK1	D	SPGAGSLGSPASQR [^]	100 nmol
MARK2	D	ASLGQASIQNGK [^]	64 nmol
MARK2	D	FLILNPSK [^]	100 nmol
MARK3	D	TPVASTHSISSAATPDR [^]	100 nmol
MARK3	D	YDEITATYLLGR [^]	100 nmol
MYLK	D	LQDVHVAEGK [^]	100 nmol
MYLK	D	TVTINTEQK [^]	100 nmol
MYLK3	D	GSLGPTLTTEAPAAAQPGK [^]	100 nmol
MYLK3	D	STGLPLAAK [^]	100 nmol
NUAK2	D	EQKPPQASGLLLHR [^]	100 nmol

NUAK2	D	IADFGLSNLYHQGK^	100 nmol
PAK1	D	DAGTLNHGSKPLPPNPEEK^	100 nmol
PAK1	D	SAEDYNSSNALNVK^	100 nmol
PAK4	D	SYLDNFIK^	63 nmol
PAK7	D	SLYGDDLDPYR^	100 nmol
PAK7	D	THPQGHSYNSYTYPR^	100 nmol
PHKG1	D	AALFENTPK^	100 nmol
PHKG1	D	LTDFGFS _c QLEPGER^	100 nmol
PKN1	D	ALQAGQLENQAAPDDTQGSPDLG AVELR^	100 nmol
PKN1	D	VLLSEFRPSGELFAIK^	100 nmol
PKN2	D	PAALTGTLEVR^	60 nmol
RIOK2	D	ESDIYIVANEEGQQFALK^	100 nmol
RIOK2	D	FSYESELFPTFK^	100 nmol
ROS1	D	TSFQFYSTLPNTIYR^	100 nmol

Primary Stock_017 (A)

Light

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
PRKCA	A	LSVEIWDWDR	100 nmol
PRKCA	A	STLNPNQWNESTFTK	100 nmol
PRKCB	A	ENIWDGVTTK	100 nmol
PRKCB	A	GTDELYAVK	100 nmol
PRKCD	A	AEFWLDLQPQAK	100 nmol
PRKCD	A	DYSNFDQEFLEK	100 nmol
PRKCE	A	LDNILLDAEGHcK	100 nmol
PRKCE	A	LGcVASQNGEDAIAK	100 nmol
PRKCG	A	LSVEVWDWDR	100 nmol
PRKCG	A	SVPSLcGVDHTEK	100 nmol
PRKCH	A	LGSLTQGGEGHAILR	100 nmol
PRKCH	A	NHPFLTQLFccFQTPDR	100 nmol
PRKCI	A	ELVNDDDEDIDWVQTEK	100 nmol
PRKCI	A	LYcANGHTFQAK	100 nmol
PRKCQ	A	SPFDcSNFDK	100 nmol
PRKCQ	A	SPTFcEHcGTLLWGLAR	100 nmol
PRKDC	A	AALSALLESFLK	100 nmol
PRKDC	A	TVGALQVLGTEAQSSLLK	100 nmol
RIPK2	A	SPSLNLLQNK	59 nmol
RIPK4	A	FQGGHGAATLLR	100 nmol
RIPK4	A	NASVNEVDFEGR	100 nmol
STK17A	A	HPWLTQSSIQEPSFR	100 nmol
STK17A	A	IVDFGLSR	100 nmol
STK17A	A	TEPFQDGYSLcPGR	100 nmol
STK17B	A	AEILHEIAVLELAK	100 nmol
STK17B	A	SISGLLTTPQIPIK	100 nmol
STK24	A	NLENGALQPSDLDR	100 nmol
STK24	A	SQAcGGNLGSIEELR	100 nmol
STK3	A	TLIEDEIATILK	100 nmol
STK3	A	VPQDGDGDFDLK	100 nmol
STK38	A	LGLEDFESLK	63 nmol
STK38	A	LSDFGLcTGLK	64 nmol

Heavy

HUGO Gene Symbol	Group Name	Peptide Sequence	Vendor Vial Amount
PRKCA	A	LSVEIWDWDR [^]	100 nmol
PRKCA	A	STLNPQWNESFTFK [^]	100 nmol
PRKCB	A	ENIWDGVTTK [^]	100 nmol
PRKCB	A	GTDELYAVK [^]	100 nmol
PRKCD	A	AEFWLDLQPQAK [^]	100 nmol
PRKCD	A	DYSNFDQEFLEK [^]	100 nmol
PRKCE	A	LDNILLDAEGHcK [^]	100 nmol
PRKCE	A	LGcVASQNGEDAIAK [^]	100 nmol
PRKCG	A	LSVEVWDWDR [^]	100 nmol
PRKCG	A	SVPSLcGVDHTEK [^]	100 nmol
PRKCH	A	LGSLTQGGEHAILR [^]	100 nmol
PRKCH	A	NHPFLTQLFcFQTPDR [^]	100 nmol
PRKCI	A	ELVNDDDEDIDWVQTEK [^]	100 nmol
PRKCI	A	LYcANGHTFQAK [^]	100 nmol
PRKCQ	A	SPFDcSNFDK [^]	100 nmol
PRKCQ	A	SPTFcEHcGTLLWGLAR [^]	100 nmol
PRKDC	A	AALSALLESFLK [^]	100 nmol
PRKDC	A	TVGALQVLGTEAQSSLLK [^]	100 nmol
RIPK2	A	SPSLNLLQNK [^]	51 nmol
RIPK4	A	FQGGHGPAATLLR [^]	100 nmol
RIPK4	A	NASVNEVDFEGR [^]	100 nmol
STK17A	A	HPWLTQSSIQEPSFR [^]	100 nmol
STK17A	A	IVDFGLSR [^]	100 nmol
STK17A	A	TEPFQDGYSLcPGR [^]	100 nmol
STK17B	A	AEILHEIAVLELAK [^]	100 nmol
STK17B	A	SISGLLTTPQIPIK [^]	100 nmol
STK24	A	NLENGALQPSDLDR [^]	100 nmol
STK24	A	SQAcGGNLGSIEELR [^]	100 nmol
STK3	A	TLIEDEIATILK [^]	100 nmol
STK3	A	VPQDGDGDFLFLK [^]	100 nmol
STK38	A	LGLEDVESLK [^]	55 nmol
STK38	A	LSDFGLcTGLK [^]	67 nmol